Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001013594-13-000547
Filing Date
2013-11-18
Accepted
2013-11-18 17:13:20
Documents
1

Document Format Files

Seq Description Document Type Size
1 NOVEMBER 15, 2013 navidea13da-111513.htm SC 13D/A 94983
  Complete submission text file 0001013594-13-000547.txt   96628
Mailing Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017
Business Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Subject) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-43603 | Film No.: 131227732
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Business Address 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 (212) 582-2222
Platinum-Montaur Life Sciences, LLC (Filed by) CIK: 0001404598 (see all company filings)

EIN.: 260204840 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A